SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
THERAPEUTIC INTERVENTIONS FOR HIV TREATMENT AND ERADICATION
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
8 of
8
|
CABOTEGRAVIR + RILPIVIRINE EVERY 2 MONTHS IS NONINFERIOR TO MONTHLY: ATLAS-2M STUDY (ABSTRACT
34)
Edgar Turner Overton
University of Alabama, Birmingham, AL, USA
PROSPECTIVE ENHANCED MONITORING OF DOLUTEGRAVIR-BASED FIRST LINE IN MALAWI (ABSTRACT
35)
Elvis Temfack
Medecins Sans Frontieres, Blantyre, Malawi
RANDOMIZED SWITCH TO B/F/TAF IN AFRICAN AMERICAN ADULTS WITH HIV (ABSTRACT
36)
Debbie P Hagins
Chatham CARE Center, Savannah, GA, USA
IMPACT OF ANTI-PD-1 AND ANTI-CTLA-4 ON THE HIV RESERVOIR IN VIVO: THE AMC-095 STUDY (ABSTRACT
37)
Thomas Aagaard Rasmussen
University of Melbourne, Melbourne, Victoria, Australia
A RANDOMIZED TRIAL OF THE IMPACT OF 3BNC117 AND ROMIDEPSIN ON THE HIV-1 RESERVOIR (ABSTRACT
38)
Ole Schmeltz Søgaard
Aarhus University Hospital, Aarhus N, Denmark
SAFETY & PHARMACOKINETICS OF GS-9722 IN HIV-NEGATIVE PARTICIPANTS AND PEOPLE WITH HIV (ABSTRACT
39)
Peter Ruane
Peter J Ruane, MD Inc, Los Angeles, CA, USA
SAFETY AND ANALYTIC TREATMENT INTERRUPTION OUTCOMES OF VESATOLIMOD IN HIV CONTROLLERS (ABSTRACT
40)
Devi Sengupta
Gilead Sciences, Foster City, CA, USA
DURABLE HIV-1 ANTIBODY PRODUCTION IN HUMANS AFTER AAV8-MEDIATED GENE TRANSFER (ABSTRACT
41)
Joseph P Casazza
National Institutes of Health, USA, Bethesda, MD, USA
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
8 of
8
|
